ALSO NOTED: Cubist wins priority review; Solexa inks $65M private placement; Swedish, Chinese firms extend collaboration; and m

> Boehringer Ingelheim reported positive results for its HIV treatment, Aptivus. Release

> Cubist Pharmaceuticals has won priority review for Cubicin as a treatment for heart valve infections. Article

> Solexa has struck a deal for a $65 million private placement. Release

> Sweden's Medivir and China's Hengrui Medicine Company have extended their two-year research collaboration developing drugs against COPD. Release

> Canada's SemBioSys Genetics has arranged $2.5 million in long-term debt financing. Release

> Canada's AEterna Zentaris has completed enrollment in a Phase II study of ozarelix in benign prostatic hyperplasia. Release

> Neurome has expanded its research collaboration with Wyeth. Release

> Carrington Laboratories of Irving, TX, has closed on a $5 million private placement. Release

And Finally… The number of people infected with the HIV virus has climbed to a record 40.3 million people, most in the developing world. Article